Cargando…

Evaluating safety and compatibility of anti-tumor necrosis factor therapy in patients with connective tissue disorders

Inhibition of the proinflammatory cytokine tumor necrosis factor alpha (TNFα) has been utilized as a treatment strategy for a variety of immune-mediated inflammatory disorders (IMID), including rheumatoid arthritis, Crohn’s disease and psoriasis. A wide array of biologic therapies targeting the TNFα...

Descripción completa

Detalles Bibliográficos
Autores principales:	Said, Jordan T., Elman, Scott A., Merola, Joseph F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article on Rheumatologic Skin Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033307/ https://www.ncbi.nlm.nih.gov/pubmed/33842651 http://dx.doi.org/10.21037/atm-20-5552

Ejemplares similares

Pruritus in autoimmune connective tissue diseases
por: Kim, Hee Joo
Publicado: (2021)

AB001. Understanding transcriptional connections of chronic cutaneous lupus erythematosus between humans and animal models
por: Banovic, Frane, et al.
Publicado: (2021)

AB014. Developing classification criteria for skin-predominant dermatomyositis: assessing the methodology of the prospective validation study
por: Concha, Josef Symon S., et al.
Publicado: (2021)

AB003. Increased CD69+ tissue-resident memory T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials
por: Zeidi, Majid, et al.
Publicado: (2021)

AB023. An atypical clinical presentation of alopecia in two patients with systemic lupus erythematosus
por: Lerman, Irina, et al.
Publicado: (2021)

AB025. Acute arthritis with dermatitis: a case of multicentric reticulohistiocytosis
por: Niaki, Omid Zahedi, et al.
Publicado: (2021)

AB007. Worse skin disease severity may distinguish patients who progress from cutaneous lupus erythematous to systemic lupus erythematous
por: Walocko, Frances, et al.
Publicado: (2021)

The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review
por: Chakka, Srita, et al.
Publicado: (2021)

AB017. Increased dendritic cells and IFN-beta and MxA protein expression in spongiotic dermatitis differentiates dermatomyositis from eczema
por: Zeidi, Majid, et al.
Publicado: (2021)

AB020. A case report on cutaneous necrotizing vasculitis treated with colchicine in a Filipino adult male
por: Cruz, Luisa Marie S., et al.
Publicado: (2021)

AB018. Myeloid dendritic cells (mDCs) are major producers of interferon-beta in dermatomyositis and increased numbers of mDCs are found in hydroxychloroquine nonresponders
por: Chen, Kristen L., et al.
Publicado: (2021)

AB009. Successful treatment of severe systemic lupus erythematosus and psoriasis with IL-17A inhibition
por: Robinett, Danielle M., et al.
Publicado: (2021)

AB006. A modular analysis approach to studying gene expression in cutaneous lupus erythematosus
por: Zhu, Jane, et al.
Publicado: (2021)

AB015. Skin disease activity and autoantibody phenotype are major determinants of blood interferon signatures in dermatomyositis
por: Tabata, Mika, et al.
Publicado: (2021)

AB013. CXCL4-DNA immune complexes drive inflammation in systemic sclerosis by amplifying TLR9-mediated interferon-α production
por: Lee, Ernest Y., et al.
Publicado: (2021)

AB021. Comparing the performance of two interferon-gamma release assays in autoimmune skin disease patients: a prospective study
por: Krain, Rebecca L., et al.
Publicado: (2021)

AB011. A Gottron’s papule mimicker: an unusual presentation of porokeratosis plantaris palmaris et disseminata
por: Schoenberg, Elizabeth, et al.
Publicado: (2021)

AB016. A double-blind, placebo-controlled, phase 2 trial of a novel toll-like receptor 7/8/9 antagonist (IMO-8400) in dermatomyositis
por: Kim, Yoo Jung, et al.
Publicado: (2021)

AB004. Evaluating differences in meaningful change in disease activity between different races and clinical subtypes affected by cutaneous lupus erythematosus
por: Chakka, Srita, et al.
Publicado: (2021)

AB012. Clinical and demographic features of morphea patients with mucocutaneous involvement: a cross sectional study from the morphea of adults and children (MAC cohort)
por: Prasad, Smriti, et al.
Publicado: (2021)

AB019. Response to tofacitinib in a case of refractory TIF-1 positive amyopathic dermatomyositis with arthritis
por: Jasmine, Sion Ward, et al.
Publicado: (2021)

AB002. Quality of life is inversely related to income in patients with cutaneous lupus
por: Prasad, Smriti, et al.
Publicado: (2021)

Why rheumatologic skin disease?
por: Sontheimer, Richard D., et al.
Publicado: (2021)

AB024. A case of bullous systemic lupus erythematosus confined to the oral mucosa
por: Strunck, Jennifer, et al.
Publicado: (2021)

AB008. Utility of repeat latent tuberculosis testing in patients with immune-mediated diseases taking biologics
por: Khanna, Urmi, et al.
Publicado: (2021)

AB005. Assessing meaningful changes in disease activity as clinical trial clinical efficacy measures for cutaneous lupus erythematosus
por: Chakka, Srita, et al.
Publicado: (2021)

AB010. Keloidal scleroderma with isolated intertriginous involvement
por: Balakrishnan, Vijay, et al.
Publicado: (2021)

AB022. Biologics and vaccination: relationship of influenza, pneumonia and zoster
por: Patel, Deep, et al.
Publicado: (2021)

Prevalence and Pattern of Pulmonary Manifestation in Patients with Connective Tissue Disorder
por: Dahani, Assadullah, et al.
Publicado: (2020)

Autoamputation and Polyneuropathy in Mixed Connective Tissue Disorder: A Case Report
por: Naqvi, Syeda, et al.
Publicado: (2017)

Weight Gain in Seropositive Rheumatoid Arthritis Patients Treated With Anti-tumor Necrosis Factor (TNF) Therapy
por: Alsulaim, Toka M, et al.
Publicado: (2022)

Mixed Connective Tissue Disorder Complicated by Polymyositis, Sjogren’s Syndrome, Pleural Effusion and Pericarditis
por: Kundi, Maryam, et al.
Publicado: (2016)

Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome: Case Report and Review of an Auto-inflammatory Disorder
por: Quintero, Javier, et al.
Publicado: (2019)

Morphea: progress to date and the road ahead
por: Abbas, Laila, et al.
Publicado: (2021)

Covert clues: the non-hallmark cutaneous manifestations of dermatomyositis
por: Castillo, Rochelle L., et al.
Publicado: (2021)

Environmental triggers of dermatomyositis: a narrative review
por: Bax, Christina E., et al.
Publicado: (2021)

Systemic sclerosis (scleroderma): remaining challenges
por: Connolly, Mary Karin
Publicado: (2021)

Dermatomyositis autoantibodies: how can we maximize utility?
por: Hodgkinson, Luqman Mushila, et al.
Publicado: (2021)

Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening?
por: Khanna, Urmi, et al.
Publicado: (2021)

Polishing the crystal ball: mining multi-omics data in dermatomyositis
por: Castillo, Rochelle L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eq5ejtafmf55483b8d965uqtl0